Login
Register
Need Help?
ABOUT
ABOUT THE EGA
EGA
Privacy Notice
Security
Team
STATISTICS
Bibliography
Growth
Community
Archive
Distribution
Catalog
PROJECTS AND FUNDERS
Projects
Funders
GA4GH
Federated EGA
Beacon
DISCOVERY
CATALOGUE
Studies
Datasets
DACs
Synthetic Data
METADATA
Search Box
Public Metadata API
SUBMISSION
DATA
File preparation
Uploading files
METADATA
EGA Schema
Sequencing & Phenotype
Submitter Portal
Submitter Portal API
Array
Programmatic Submission XML
ACCESS
DATA ACCESS COMMITTEE
What is a DAC?
Best Practices
DAC Portal
Data Use Conditions
REQUEST DATA
How to request data?
Quality Control Reports
DOWNLOAD
Metadata
Files
PyEGA3
Live Outbox
Visualisation
FUSE Client
EGA QuickView
Tips on how to search
DACs
EGAC50000000233
Tampere University Celiac Disease Research Data Access Committee
Contact Information
Dr Keijo Viiri
keijo.viiri@tuni.fi
Request Access
This DAC controls 2 datasets
Dataset ID
Description
Technology
Samples
EGAD50000000491
Samples, in a form of PAXgene fixed and paraffin-embedded biopsies, were collected from the multi-site, double-blind, randomized, placebo-controlled trial, aimed at dose-finding and assessing the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge. Total RNA was extracted from the PaxFPE biopsy specimens (n = 116) using additional cuttings from the samples on which histomorphometry was previously assessed. For the extraction, an RNeasy Kit (Qiagen, Hilden, Germany) was used according to the manufacturer’s instructions. Library preparation and next-generation sequencing (NGS) were performed by the Qiagen NGS Service. A total of 10 ng of purified RNA was converted into cDNA NGS libraries. Library preparation was quality controlled using capillary electrophoresis. Based on the quality of the inserts and the concentration measurements, the libraries were pooled in equimolar ratios and then sequenced on a NextSeq (Illumina Inc., San Diego, USA) sequencing instrument according to the manufacturer’s instructions, with 100 bp read length for read 1 and 27bp for read 2. The raw data were de-multiplexed, and FASTQ files for each sample were generated using bcl2fastq2 software (Illumina Inc., San Diego, USA).
NextSeq 550
116
EGAD50000000492
uman duodenal tissues for establishing organoid cultures used in this study were sourced from de-identified surgical specimens (n = 3) of the duodenum obtained from patients who had undergone biopsy procedures unrelated to CeD at Tampere University Hospital. The protocol was approved by the Ethics Committee of Tampere University Hospital, Tampere, Finland (ETL code R18082). RNA from the duodenal organoids was isolated using an RNeasy Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. RNA purity and concentration were measured using a NanoDrop One spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA). Preparation of the RNA library and transcriptome sequencing was conducted by Novogene Co., LTD (Cambridge, UK). Messenger RNA was purified from total RNA using polyA selection and subjected to library construction. Sequencing was performed on an Illumina platform, and 150 bp paired-end reads were generated.
Illumina NovaSeq 6000
11